Canadian Markets open in 3 hrs.

AstraZeneca PLC (AZN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
33.78-0.07 (-0.21%)
At close: 4:02PM EDT

33.85 0.05 (0.15%)
Pre-Market: 6:15AM EDT

People also watch
Full screen
Previous Close33.85
Bid33.85 x 2000
Ask33.87 x 1700
Day's Range33.63 - 34.05
52 Week Range25.55 - 35.60
Avg. Volume4,434,184
Market Cap82.35B
PE Ratio (TTM)25.30
EPS (TTM)1.34
Earnings DateN/A
Dividend & Yield1.90 (5.61%)
Ex-Dividend Date2017-02-15
1y Target Est34.87
Trade prices are not sourced from all markets
  • Market Realist13 hours ago

    Vertex: Why Label Expansion Could Boost Orkambi Sales in 2017

    ertex Pharmaceuticals’ Orkambi also secured U.S. Food and Drug Administration’s (or FDA) approval for CF patients in the age group of six to 11 years in September 2016.

  • Biotechs On A Hot Streak, And Could Be 'Cooking With Gas'
    Investor's Business Daily5 days ago

    Biotechs On A Hot Streak, And Could Be 'Cooking With Gas'

    IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?

  • Reuters - UK Focus5 days ago

    GlaxoSmithKline's new CEO prepares to trim drug pipeline

    GlaxoSmithKline (Other OTC: GLAXF - news) 's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.